title: Effect of two modes of antiandrogen treatment on insulin sensitivity and serum leptin in women with PCOS.
abstract: Androgens are suggested to interact with leptin production and with insulin sensitivity in both polycystic ovary syndrome (PCOS) and obesity. The aim of the study was to follow these interactions along with two forms of antiandrogen treatment. Twenty women with PCOS were treated with ethinylestradiol and high dose of cyproteroneacetate (EE-CA) and 8 with the gonadotrophin-releasing hormone (GnRH) analogue goserelin for 6 months. The patients were divided into a low and a high body weight group and compared with a group of overweight women without PCOS. Both treatments resulted in a significant reduction of free testosterone but the concentration of leptin remained unchanged. EECA treatment resulted in deterioration and GnRH in improvement of insulin sensitivity. Serum leptin correlated only with body weight and body fat. It is concluded that leptin levels do not adequately reflect changes in insulin sensitivity or androgen levels after short-term antiandrogen or antigonadotropin treatment.
authors.affiliation: Department of Rehabilitation Medicine, Sahlgrenska University Hospital, Göteborg, Sweden. m.krotkiewski@multipharma.com
authors.forename: Marcin
authors.initials: M
authors.lastname: Krotkiewski
authors.forename: Kerstin
authors.initials: K
authors.lastname: Landin
authors.forename: Eva
authors.initials: E
authors.lastname: Dahlgren
authors.forename: Per Olof
authors.initials: PO
authors.lastname: Janson
authors.forename: Göran
authors.initials: G
authors.lastname: Holm
mesh_terms: D000273:Adipose Tissue; D000328:Adult; D000726:Androgen Antagonists / Q000627:therapeutic use*; D001054:Apolipoproteins A / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D001823:Body Composition; D001824:Body Constitution; D015992:Body Mass Index; D001835:Body Weight; D002096:C-Peptide / Q000097:blood; D017373:Cyproterone Acetate / Q000627:therapeutic use; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D017273:Goserelin / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D020738:Leptin / Q000097:blood*; D017270:Lipoprotein(a) / Q000097:blood; D009765:Obesity / Q000097:blood / Q000150:complications; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D013739:Testosterone / Q000097:blood; D014280:Triglycerides / Q000097:blood
chemical_list: D000726:Androgen Antagonists; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D020738:Leptin; D017270:Lipoprotein(a); D012738:Sex Hormone-Binding Globulin; D014280:Triglycerides; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D019314:Dehydroepiandrosterone Sulfate